189 related articles for article (PubMed ID: 23868727)
21. Antroquinonol Targets FAK-Signaling Pathway Suppressed Cell Migration, Invasion, and Tumor Growth of C6 Glioma.
Thiyagarajan V; Tsai MJ; Weng CF
PLoS One; 2015; 10(10):e0141285. PubMed ID: 26517117
[TBL] [Abstract][Full Text] [Related]
22. FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo.
Gillory LA; Stewart JE; Megison ML; Nabers HC; Mroczek-Musulman E; Beierle EA
Transl Oncol; 2013 Apr; 6(2):206-15. PubMed ID: 23544173
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.
Beierle EA; Ma X; Trujillo A; Kurenova EV; Cance WG; Golubovskaya VM
Mol Carcinog; 2010 Mar; 49(3):224-34. PubMed ID: 19885861
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.
Kurenova EV; Hunt DL; He D; Fu AD; Massoll NA; Golubovskaya VM; Garces CA; Cance WG
Cell Cycle; 2009 Jul; 8(14):2266-80. PubMed ID: 19556880
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.
Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
Mol Cancer Ther; 2015 Jul; 14(7):1559-69. PubMed ID: 25944918
[TBL] [Abstract][Full Text] [Related]
27. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
Kang Y; Hu W; Ivan C; Dalton HJ; Miyake T; Pecot CV; Zand B; Liu T; Huang J; Jennings NB; Rupaimoole R; Taylor M; Pradeep S; Wu SY; Lu C; Wen Y; Huang J; Liu J; Sood AK
J Natl Cancer Inst; 2013 Oct; 105(19):1485-95. PubMed ID: 24062525
[TBL] [Abstract][Full Text] [Related]
28. MeHg affects the activation of FAK, Src, Rac1 and Cdc42, critical proteins for cell movement in PDGF-stimulated SH-SY5Y neuroblastoma cells.
Hernández AJA; Reyes VL; Albores-García D; Gómez R; Calderón-Aranda ES
Toxicology; 2018 Feb; 394():35-44. PubMed ID: 29197552
[TBL] [Abstract][Full Text] [Related]
29. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
30. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Sun Q; Zhou J; Zhang Z; Guo M; Liang J; Zhou F; Long J; Zhang W; Yin F; Cai H; Yang H; Zhang W; Gu Y; Ni L; Sai Y; Cui Y; Zhang M; Hong M; Sun J; Yang Z; Qing W; Su W; Ren Y
Cancer Biol Ther; 2014; 15(12):1635-45. PubMed ID: 25482937
[TBL] [Abstract][Full Text] [Related]
31. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
[TBL] [Abstract][Full Text] [Related]
32. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.
Kandil S; Prencipe F; Jones S; Hiscox S; Westwell AD
Chem Biol Drug Des; 2018 Jan; 91(1):314-321. PubMed ID: 28816016
[TBL] [Abstract][Full Text] [Related]
33. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
Bäckman U; Christofferson R
Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
[TBL] [Abstract][Full Text] [Related]
34. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
[TBL] [Abstract][Full Text] [Related]
35. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis.
Golubovskaya VM; Zheng M; Zhang L; Li JL; Cance WG
BMC Cancer; 2009 Aug; 9():280. PubMed ID: 19671193
[TBL] [Abstract][Full Text] [Related]
36. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
37. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
38. Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells.
Waters AM; Stafman LL; Garner EF; Mruthyunjayappa S; Stewart JE; Mroczek-Musulman E; Beierle EA
Transl Oncol; 2016 Aug; 9(4):263-73. PubMed ID: 27567948
[TBL] [Abstract][Full Text] [Related]
39. N-MYC regulates focal adhesion kinase expression in human neuroblastoma.
Beierle EA; Trujillo A; Nagaram A; Kurenova EV; Finch R; Ma X; Vella J; Cance WG; Golubovskaya VM
J Biol Chem; 2007 Apr; 282(17):12503-16. PubMed ID: 17327229
[TBL] [Abstract][Full Text] [Related]
40. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
Golubovskaya VM; Figel S; Ho BT; Johnson CP; Yemma M; Huang G; Zheng M; Nyberg C; Magis A; Ostrov DA; Gelman IH; Cance WG
Carcinogenesis; 2012 May; 33(5):1004-13. PubMed ID: 22402131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
